Suppr超能文献

肝硬化患者的血清氨:高氨血症的临床影响、检测的实用性及全国检测趋势。

Serum Ammonia in Cirrhosis: Clinical Impact of Hyperammonemia, Utility of Testing, and National Testing Trends.

机构信息

Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

出版信息

Clin Ther. 2022 Mar;44(3):e45-e57. doi: 10.1016/j.clinthera.2022.01.008. Epub 2022 Feb 4.

Abstract

PURPOSE

Ammonia is central to the pathophysiology of hepatic encephalopathy (HE) in cirrhosis. Serum ammonia levels have prognostic value and have been implicated in sarcopenia, hepatotoxicity, and immune dysfunction. Studies indicate that clinicians frequently order serum ammonia levels in decompensated cirrhosis; however, the clinical utility of serum ammonia levels has been questioned, citing challenges in accurate measurement and interpretation. This article involves a primary review of the literature to evaluate the importance of serum ammonia in cirrhosis and examines the clinical utility of serum ammonia levels in the management of HE. In addition to the review, we conducted primary research using national claims data to investigate national trends in practitioner use of serum ammonia.

METHODS

We identified all hospitalizations in a national commercial claims database with and without ammonia testing among adults with noncirrhotic chronic liver disease and cirrhosis from January 1, 2007, to September 31, 2015. We calculated the proportion of hospitalizations with ammonia testing and the number of ammonia tests per 1000 hospital-days.

FINDINGS

Proportion of hospitalizations with ammonia testing and ammonia tests per 1000 inpatient-days increased significantly from 2007 to 2015, and particularly in 2014 and 2015, for all groups.

IMPLICATIONS

A review of the literature indicated that elevated serum ammonia contributes to neurotoxicity, sarcopenia, and immune dysfunction in cirrhosis. However, serum ammonia testing has not had consistent benefit in clinical diagnosis or management of HE in cirrhosis. Claims data indicated that ammonia testing increased substantially during the study period, particularly after the advent of electronic medical record systems. The rapid increase in testing may suggest that electronic health records play a crucial role in test volume by facilitating easy ordering and could be leveraged to improved value-based serum ammonia ordering. Serum ammonia levels may also benefit from standardized guidelines on collection, laboratory analysis, and interpretation.

摘要

目的

氨在肝硬化肝性脑病(HE)的病理生理学中起着核心作用。血清氨水平具有预后价值,并与肌肉减少症、肝毒性和免疫功能障碍有关。研究表明,临床医生经常在失代偿性肝硬化中检测血清氨水平;然而,由于准确测量和解释方面的挑战,血清氨水平的临床实用性受到了质疑。本文主要对文献进行了回顾,以评估血清氨在肝硬化中的重要性,并研究了血清氨水平在 HE 管理中的临床应用。除了综述,我们还利用国家索赔数据进行了初步研究,以调查全国医生使用血清氨的趋势。

方法

我们从 2007 年 1 月 1 日至 2015 年 9 月 31 日,在全国商业索赔数据库中确定了所有非肝硬化慢性肝病和肝硬化成人住院患者的检测和未检测氨的住院病例。我们计算了检测氨的住院患者比例以及每 1000 个住院日的氨检测次数。

结果

从 2007 年到 2015 年,所有组别的检测氨的住院患者比例和每 1000 个住院日的氨检测次数都显著增加,尤其是在 2014 年和 2015 年。

意义

文献综述表明,血清氨升高会导致肝硬化中的神经毒性、肌肉减少症和免疫功能障碍。然而,血清氨检测在肝硬化 HE 的临床诊断或管理中并没有一致的获益。索赔数据表明,在研究期间,检测数量大幅增加,尤其是在电子病历系统出现之后。检测数量的快速增加可能表明电子病历系统通过方便的医嘱输入在检测量方面发挥了关键作用,并可以利用这一点来改进基于价值的血清氨医嘱输入。血清氨水平也可能受益于关于采集、实验室分析和解释的标准化指南。

相似文献

1
Serum Ammonia in Cirrhosis: Clinical Impact of Hyperammonemia, Utility of Testing, and National Testing Trends.
Clin Ther. 2022 Mar;44(3):e45-e57. doi: 10.1016/j.clinthera.2022.01.008. Epub 2022 Feb 4.
2
Hepatic Encephalopathy-A Guide to Laboratory Testing.
Clin Liver Dis. 2024 May;28(2):225-236. doi: 10.1016/j.cld.2024.01.003. Epub 2024 Jan 30.
3
The Ongoing Debate of Serum Ammonia Levels in Cirrhosis: the Good, the Bad, and the Ugly.
Am J Gastroenterol. 2023 Jan 1;118(1):10-13. doi: 10.14309/ajg.0000000000001966. Epub 2022 Aug 23.
4
Ammonia levels and the severity of hepatic encephalopathy.
J Coll Physicians Surg Pak. 2014 Mar;24(3):160-3.
6
Is sarcopenia associated with hepatic encephalopathy in liver cirrhosis? A systematic review and meta-analysis.
J Formos Med Assoc. 2019 Apr;118(4):833-842. doi: 10.1016/j.jfma.2018.09.011. Epub 2018 Sep 29.
7
Serum ammonia does not guide management and is overutilised in patients with cirrhosis in hospital settings.
Intern Med J. 2023 Nov;53(11):2057-2064. doi: 10.1111/imj.16053. Epub 2023 Apr 3.
8
The Role of Sarcopenia and Frailty in Hepatic Encephalopathy Management.
Clin Liver Dis. 2015 Aug;19(3):507-28. doi: 10.1016/j.cld.2015.04.003.
9
The Value of Ammonia as a Biomarker in Patients with Cirrhosis.
Semin Liver Dis. 2024 Aug;44(3):356-368. doi: 10.1055/a-2378-8942. Epub 2024 Aug 2.
10
Breath and blood ammonia in liver cirrhosis.
Hepatogastroenterology. 2000 Mar-Apr;47(32):443-5.

引用本文的文献

1
Ammonia-to-Urea Ratio: A Noninvasive First-Line Tool for Detecting Clinically Significant Portal Hypertension.
JGH Open. 2025 Sep 8;9(9):e70273. doi: 10.1002/jgh3.70273. eCollection 2025 Sep.
2
Inherited metabolic disorders: presentation, clinical types, laboratory diagnosis and genetic markers.
Orphanet J Rare Dis. 2025 Aug 11;20(1):422. doi: 10.1186/s13023-025-03979-8.
5
Construction of a prediction model for hepatic encephalopathy in acute-on-chronic liver failure patients.
Ann Med. 2024 Dec;56(1):2410403. doi: 10.1080/07853890.2024.2410403. Epub 2024 Oct 10.
6
The Value of Ammonia as a Biomarker in Patients with Cirrhosis.
Semin Liver Dis. 2024 Aug;44(3):356-368. doi: 10.1055/a-2378-8942. Epub 2024 Aug 2.
7
Physiological network approach to prognosis in cirrhosis: A shifting paradigm.
Physiol Rep. 2024 Jul;12(13):e16133. doi: 10.14814/phy2.16133.
10
Inpatient management of hepatic encephalopathy.
Clin Liver Dis (Hoboken). 2024 Feb 4;23(1):e0105. doi: 10.1097/CLD.0000000000000105. eCollection 2024 Jan-Jun.

本文引用的文献

2
Reply.
Clin Gastroenterol Hepatol. 2021 Nov;19(11):2457-2458. doi: 10.1016/j.cgh.2021.02.020. Epub 2021 Feb 12.
3
Erroneous Ammonia Measurement is Not Synonymous With a Lack of Efficacy of Ammonia-Lowering Therapies in Hepatic Encephalopathy.
Clin Gastroenterol Hepatol. 2021 Nov;19(11):2456-2457. doi: 10.1016/j.cgh.2021.01.046. Epub 2021 Jan 29.
4
A Prospective, Blinded Assessment of Ammonia Testing Demonstrates Low Utility Among Front-Line Clinicians.
Clin Gastroenterol Hepatol. 2022 Apr;20(4):e895-e896. doi: 10.1016/j.cgh.2021.01.016. Epub 2021 Jan 13.
5
Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial.
Clin Gastroenterol Hepatol. 2021 Dec;19(12):2626-2635.e7. doi: 10.1016/j.cgh.2020.10.019. Epub 2020 Oct 16.
6
Incidence of and Risk Factors for Hepatic Encephalopathy in a Population-Based Cohort of Americans With Cirrhosis.
Hepatol Commun. 2019 Sep 6;3(11):1510-1519. doi: 10.1002/hep4.1425. eCollection 2019 Nov.
7
Ammonia Levels Do Not Guide Clinical Management of Patients With Hepatic Encephalopathy Caused by Cirrhosis.
Am J Gastroenterol. 2020 May;115(5):723-728. doi: 10.14309/ajg.0000000000000343.
9
Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver Disease.
Hepatology. 2020 Mar;71(3):874-892. doi: 10.1002/hep.30890. Epub 2019 Oct 15.
10
Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.
Cochrane Database Syst Rev. 2019 Jun 17;6(6):CD012334. doi: 10.1002/14651858.CD012334.pub2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验